Caregen Co.Ltd (214370) - Total Liabilities
Based on the latest financial reports, Caregen Co.Ltd (214370) has total liabilities worth ₩17.10 Billion KRW (≈ $11.59 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 214370 cash flow metrics to assess how effectively this company generates cash.
Caregen Co.Ltd - Total Liabilities Trend (2015–2024)
This chart illustrates how Caregen Co.Ltd's total liabilities have evolved over time, based on quarterly financial data. Check Caregen Co.Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.
Caregen Co.Ltd Competitors by Total Liabilities
The table below lists competitors of Caregen Co.Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Telsys
TA:TLSY
|
Israel | ILA156.38 Million |
|
Link Mobility Group Holding ASA
OL:LINK
|
Norway | Nkr5.22 Billion |
|
Jilin Liyuan Precision Manufacturing Co Ltd
SHE:002501
|
China | CN¥720.23 Million |
|
Redtape Limited
NSE:REDTAPE
|
India | Rs14.33 Billion |
|
Butterfly Network Inc
NYSE:BFLY
|
USA | $86.17 Million |
|
Eagle Bancorp Inc
NASDAQ:EGBN
|
USA | $9.36 Billion |
|
Sunway Co Ltd
SHG:603333
|
China | CN¥797.05 Million |
|
Canadian General Investments Ltd
TO:CGI
|
Canada | CA$202.17 Million |
Liability Composition Analysis (2015–2024)
This chart breaks down Caregen Co.Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 214370 stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Caregen Co.Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Caregen Co.Ltd (2015–2024)
The table below shows the annual total liabilities of Caregen Co.Ltd from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩17.72 Billion ≈ $12.01 Million |
-11.31% |
| 2023-12-31 | ₩19.98 Billion ≈ $13.54 Million |
+10.43% |
| 2022-12-31 | ₩18.09 Billion ≈ $12.26 Million |
+6.16% |
| 2021-12-31 | ₩17.04 Billion ≈ $11.55 Million |
+49.55% |
| 2020-12-31 | ₩11.40 Billion ≈ $7.72 Million |
-23.20% |
| 2019-12-31 | ₩14.84 Billion ≈ $10.06 Million |
+4.61% |
| 2018-12-31 | ₩14.18 Billion ≈ $9.61 Million |
-6.65% |
| 2017-12-31 | ₩15.19 Billion ≈ $10.30 Million |
+1.14% |
| 2016-12-31 | ₩15.02 Billion ≈ $10.18 Million |
+96.52% |
| 2015-12-31 | ₩7.65 Billion ≈ $5.18 Million |
-- |
About Caregen Co.Ltd
Caregen Co., Ltd. engages in the research, development, and commercialization of biomimetic peptides and growth factors worldwide. The company offers cosmeceutical products and food supplements under the Dermaheal, Renokin, Deglusterol, PURILUX, Pelo Baum, Pim-Pim-Paul, Neovert, and PTx brands. It also provides medical devices under the REVOFIL, DR.CYJ, PROSTROLANE, PROSTROLANE B-Series, and CG S… Read more